Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 3, 2026 · Other material event · Financial statements
TG THERAPEUTICS, INC.
8
Other material event
Jun 3, 2026
| Form type | Current report (Form 8-K) |
| Event summary | Other material event · Financial statements |
| Primary topic | Other material event |
| About this form | Public companies file this within four business days when something important happens that investors should know about, before the next quarterly report. |
| Why this was filed | TG THERAPEUTICS, INC. filed this to release information to investors under Regulation FD, usually a press release, conference presentation, or other event the company considers important. 1 TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI ® (ublituximab-xiiy) Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or early 2027 Novel Investigational high co… |
| Labor angle | Watch for Item 2.05 (restructuring or severance), Item 5.02 (leadership changes), and Item 1.01 (major contracts that can precede workforce shifts). |
| Period of report | Jun 3, 2026 |
| Accession number | 0001437749-26-019262 |
| Reported items | Other events the company considers material, Financial statements and exhibits See Analysis tab for workforce implications |
